Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
Price : $35 *
At a glance
- Drugs Irbesartan (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms SartSep
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 Status changed from not yet recruiting to discontinued.
- 06 Jan 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 19 Nov 2013).